February 12th, 2025 | 07:00 CET
Analysts on the TUI CRASH! Bayer to make millions! dynaCERT stock is set to skyrocket!
Will the dynaCERT stock see a breakthrough soon? The odds are looking good. In an analyst interview, the top German manager cites an increase in revenue, sales, and earnings as a clear goal for the next 12 months. In that case, the stock would currently be a bargain. The TUI share, however, does not appear to be a bargain for investors. The quarterly figures led to a sell-off yesterday. Yet revenue and earnings were in line with expectations. What do analysts say? Bayer's stock also trended weak yesterday, despite new potential millions in revenue from a drug approval.
time to read: 3 minutes
|
Author:
Fabian Lorenz
ISIN:
TUI AG NA O.N. | DE000TUAG505 , BAYER AG NA O.N. | DE000BAY0017 , DYNACERT INC. | CA26780A1084
Table of contents:
Author
Fabian Lorenz
For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
Tag cloud
Shares cloud
dynaCERT: Revenue, Sales, and Profits expected to increase!
When will dynaCERT's shares break out to the upside? It is only a matter of time, according to a recently published management interview with analysts from GBC Research. In the interview, Bernd Krüper outlines the patented HydraGEN technology for fuel savings, discusses the Company's growth strategy, and reveals future innovations. The German executive has several decades of experience in the automotive industry and has been serving as President and Director at dynaCERT since last year.
The hydrogen-based HydraGEN retrofit kit – which can be installed in under two hours – reduces the pollutant emissions and consumption of conventional combustion engines. It also generates emission certificates and, thus, additional revenue. The focus is particularly on users of heavy diesel vehicles in the mining, oil and gas, transportation, and power generation sectors. This market alone is huge worldwide. In addition, Krüper emphasizes that they are also receiving inquiries for other areas of application, such as in the natural gas and shipping sectors.
When asked about his specific goals for the next 12 months, Krüper gives a clear answer: "To expand dynaCERT's sales, revenue, and earnings quickly." His vision is to position dynaCERT as "THE" world-leading "upgrader" of vehicle, ship, and power generator fleets. Download the full interview here.
TUI: Analysts after the price slide
The quarterly figures from TUI were eagerly awaited. After the positive results from travel portals like Expedia, there was hope that TUI would also impress. However, that optimism was dashed. Investors were caught off guard. Despite this, the figures for the first quarter were quite respectable. Revenue rose by 13% to EUR 4.9 billion. Adjusted EBIT increased by EUR 44.9 million to EUR 50.9 million. The pre-tax loss was significantly reduced from EUR -103.1 million to EUR -37.1 million. These results were within the projected range. Nevertheless, the share price fell by more than 10% yesterday.
The negative reactions were mainly due to the development of bookings. Bookings for the current winter season 2024/25 and the summer season 2025 are only 2% higher than in the previous year. Prices, on the other hand, rose by an average of 4%. This shows that the challenging economic environment in Europe – and particularly in Germany – is now also affecting the desire to travel.
The first analyst reactions also concluded that quarterly figures were good but that the bookings situation indicated a slowdown in growth momentum. In their initial reactions, Bernstein, Jefferies, Barclays, and UBS confirmed their neutral stance on TUI shares. The target prices range from EUR 7.70 to EUR 8.28. The share is currently trading at around EUR 7.70.
Bayer: Drug approval fizzles out
Bayer was unable to benefit from positive news yesterday. The Leverkusen-based company reported that the heart drug Acoramidis may be marketed in the EU. The approval was granted for the treatment of adult patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM), a disease that damages the heart muscle. In a Phase III clinical study, Acoramidis showed clear positive effects on the frequency of hospitalizations and mortality rates. However, Bayer is the only exclusive marketer in Europe. As a result, the revenue potential for the DAX company is expected to be somewhat limited. The active ingredient was developed by the US-based company BridgeBio Pharma.
Bayer's shares fell by more than 1% yesterday and are trading at around EUR 20.70. Analysts are also reluctant to issue "Buy" recommendations at present. Bernstein and JPMorgan recently reiterated their neutral assessments.
For Bayer and TUI, it seems like the momentum has temporarily fizzled out. On the other hand, the chances look good that 2025 could be the year for dynaCERT shares. However, a few significant orders are needed for the breakthrough to happen and for the stock to soar.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
